Method of treating or preventing an IL-1 related disease or condition
AssigneeXoma Technology Ltd.
InventorsLinda Masat, Mary Haak-Frendscho, Gang Chen, Arnold Horwitz, Marina Roell
Life of this patent
Estimating the term…
Abstract
Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide is provided. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.
Claims12
An isolated nucleic acid comprising a nucleic acid sequence that encodes a heavy chain variable region of an IL-1β binding antibody or IL-1β binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:
- 15.
An isolated nucleic acid comprising a nucleic acid sequence that encodes a light chain variable region of an IL-1β binding antibody or IL-1β binding fragment thereof, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:
- 11.
An isolated nucleic acid encoding an IL-1β binding antibody or IL-1β binding fragment thereof, wherein the antibody or fragment comprises a heavy chain variable region of SEQ ID NO:
- 15 and a light chain variable region of SEQ ID NO:
- 11.
An isolated nucleic acid encoding an IL-1β binding antibody or IL-1β binding fragment thereof, wherein the antibody or fragment binds to human IL-1β with a dissociation constant less than 1 pM, and the antibody or fragment competes with the binding of an antibody comprising the heavy chain variable region of SEQ ID NO:
- 15 and the light chain variable region of SEQ ID NO:
- 11.
Dependencies are inferred from the claim text.